/antibody-and-antiviral-deployment

While vaccines remain the best strategy to prevent COVID-19, mAbs could potentially benefit certain vulnerable populations before or after exposure to SARS-CoV-2, such as the unvaccinated or recently vaccinated high-risk patients.

Primary LanguageHTMLMIT LicenseMIT

Watchers